Who can use Jaypirca(Pirtobrutinib)?

The specific medical conditions the drug is approved to treat.

Approved Uses

JAYPIRCA is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) following at least two prior systemic therapies, including a BTK inhibitor. It is also indicated for adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) who have received at least two prior lines of therapy, including both a BTK inhibitor and a BCL-2 inhibitor. These approvals were granted under the FDA's accelerated approval pathway based on observed response rates.